Literature DB >> 22287724

An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.

Shu-Chen Lu1, Larissa Atangan, Ki Won Kim, Michelle M Chen, Renee Komorowski, Carolyn Chu, Joon Han, Sylvia Hu, Wei Gu, Murielle Véniant, Minghan Wang.   

Abstract

The aim of this study is to investigate the capability of an apoA-I mimetic with multiple amphipathic helices to form HDL-like particles in vitro and in vivo. To generate multivalent helices and to track the peptide mimetic, we have constructed a peptibody by fusing two tandem repeats of 4F peptide to the C terminus of a murine IgG Fc fragment. The resultant peptidbody, mFc-2X4F, dose-dependently promoted cholesterol efflux in vitro, and the efflux potency was superior to monomeric 4F peptide. Like apoA-I, mFc-2X4F stabilized ABCA1 in J774A.1 and THP1 cells. The peptibody formed larger HDL particles when incubated with cultured cells compared with those by apoA-I. Interestingly, when administered to mice, mFc-2X4F increased both pre-β and α-1 HDL subfractions. The lipid-bound mFc-2X4F was mostly in the α-1 migrating subfraction. Most importantly, mFc-2X4F and apoA-I were found to coexist in the same HDL particles formed in vivo. These data suggest that the apoA-I mimetic peptibody is capable of mimicking apoA-I to generate HDL particles. The peptibody and apoA-I may work cooperatively to generate larger HDL particles in vivo, either at the cholesterol efflux stage and/or via fusion of HDL particles that were generated by the peptibody and apoA-I individually.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22287724      PMCID: PMC3307641          DOI: 10.1194/jlr.M020438

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  35 in total

1.  The structure of human lipoprotein A-I. Evidence for the "belt" model.

Authors:  V Koppaka; L Silvestro; J A Engler; C G Brouillette; P H Axelsen
Journal:  J Biol Chem       Date:  1999-05-21       Impact factor: 5.157

2.  Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations.

Authors:  B F Asztalos; C H Sloop; L Wong; P S Roheim
Journal:  Biochim Biophys Acta       Date:  1993-09-08

Review 3.  Molecular physiology of reverse cholesterol transport.

Authors:  C J Fielding; P E Fielding
Journal:  J Lipid Res       Date:  1995-02       Impact factor: 5.922

4.  Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides.

Authors:  P G Yancey; J K Bielicki; W J Johnson; S Lund-Katz; M N Palgunachari; G M Anantharamaiah; J P Segrest; M C Phillips; G H Rothblat
Journal:  Biochemistry       Date:  1995-06-20       Impact factor: 3.162

5.  Formation of new HDL particles from lipid-free apolipoprotein A-I.

Authors:  M A Clay; P J Barter
Journal:  J Lipid Res       Date:  1996-08       Impact factor: 5.922

6.  Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties.

Authors:  Jonas Heilskov Graversen; Jacob Marsvin Laurberg; Mikkel Holmen Andersen; Erling Falk; John Nieland; Jesper Christensen; Michael Etzerodt; Hans Christian Thøgersen; Søren Kragh Moestrup
Journal:  J Cardiovasc Pharmacol       Date:  2008-02       Impact factor: 3.105

7.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.

Authors:  C Pászty; N Maeda; J Verstuyft; E M Rubin
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

8.  Biophysical characterization of structural properties and folding of interleukin-1 receptor antagonist.

Authors:  Ramil F Latypov; Timothy S Harvey; Dingjiang Liu; Pavel V Bondarenko; Tadahiko Kohno; Roger A Fachini; Robert D Rosenfeld; Randal R Ketchem; David N Brems; Andrei A Raibekas
Journal:  J Mol Biol       Date:  2007-02-22       Impact factor: 5.469

9.  Atherogenesis in transgenic mice expressing human apolipoprotein(a)

Authors:  R M Lawn; D P Wade; R E Hammer; G Chiesa; J G Verstuyft; E M Rubin
Journal:  Nature       Date:  1992-12-17       Impact factor: 49.962

10.  Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.

Authors:  Geoffrey D Wool; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2008-03-05       Impact factor: 5.922

View more
  10 in total

1.  Cumulative Brain Injury from Motor Vehicle-Induced Whole-Body Vibration and Prevention by Human Apolipoprotein A-I Molecule Mimetic (4F) Peptide (an Apo A-I Mimetic).

Authors:  Ji-Geng Yan; Lin-ling Zhang; Michael Agresti; Yuhui Yan; John LoGiudice; James R Sanger; Hani S Matloub; Kirkwood A Pritchard; Safwan S Jaradeh; Robert Havlik
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-12       Impact factor: 2.136

2.  Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization.

Authors:  Jie Tang; Dan Li; Lindsey Drake; Wenmin Yuan; Sara Deschaine; Emily E Morin; Rose Ackermann; Karl Olsen; David E Smith; Anna Schwendeman
Journal:  J Lipid Res       Date:  2016-11-23       Impact factor: 5.922

3.  HDL Mimetic Peptides.

Authors:  Jie Chen; Jiewen Liu; Baoqi Yu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  The potential of apolipoprotein mimetic peptides in the treatment of atherosclerosis.

Authors:  Luke J Leman
Journal:  Clin Lipidol       Date:  2015-06

Review 5.  Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

Authors:  Luke J Leman; Bruce E Maryanoff; M Reza Ghadiri
Journal:  J Med Chem       Date:  2013-10-29       Impact factor: 7.446

Review 6.  Apolipoprotein A-I mimetics.

Authors:  Srinivasa T Reddy; Mohamad Navab; Gattadahalli M Anantharamaiah; Alan M Fogelman
Journal:  Curr Opin Lipidol       Date:  2014-08       Impact factor: 4.776

7.  In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.

Authors:  Yannan Zhao; Audrey S Black; David J Bonnet; Bruce E Maryanoff; Linda K Curtiss; Luke J Leman; M Reza Ghadiri
Journal:  J Lipid Res       Date:  2014-06-29       Impact factor: 5.922

8.  Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs.

Authors:  Yannan Zhao; Tomohiro Imura; Luke J Leman; Linda K Curtiss; Bruce E Maryanoff; M Reza Ghadiri
Journal:  J Am Chem Soc       Date:  2013-08-26       Impact factor: 15.419

9.  Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size.

Authors:  Herman J Kempen; Dorota B Schranz; Bela F Asztalos; James Otvos; Elias Jeyarajah; Denise Drazul-Schrader; Heidi L Collins; Steven J Adelman; Peter L J Wijngaard
Journal:  J Lipids       Date:  2014-11-12

10.  Self-Assembling Cyclic d,l-α-Peptides as Modulators of Plasma HDL Function. A Supramolecular Approach toward Antiatherosclerotic Agents.

Authors:  Yannan Zhao; Luke J Leman; Debra J Search; Ricardo A Garcia; David A Gordon; Bruce E Maryanoff; M Reza Ghadiri
Journal:  ACS Cent Sci       Date:  2017-06-13       Impact factor: 14.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.